Ready to earn up to 9% APY on your SOL?Stake PSOL in a few taps:→ Open Phantom and navigate to SOL→ Tap ‘Start Earning’→ Choose how much to stake and hit ‘Stake’→ Sit back and let the rewards roll in 😎 https://t.co/D0xxY5dG4U ...

New milestone: 325K+ PSOL minted 🎉 https://t.co/6lIaeZ1z3J ...

Wallet Connect's WCT latest airdrop is live 🎁Top 5,000 wallets by recent USD swap volume on Solana DEXs via Phantom ANDTop 5,000 pSOL holders are eligiblePhantom (@phantom):WCT airdrop claim for Phantom users is now live! 👻https://t.co/Ojxv44fdPN ...

This Investment will add a differentiated ophthalmic platform, targeting an estimated 3 million annual U.S. cataract surgeries with long-acting, “dropless” pain and inflammation treatmentTEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing proprietary, long-acting, non-opiate treatments for ophthalmic ...

NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. “We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated ...

NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today the final results and closing of its $25.0 million rights offering (the “Rights Offering”). The subscription period of the Rights Offering expired at 5:00 P.M. Eastern Time, on May 29, 2025. The Rights Offering resulted in subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share for aggregate gross proceeds of $4,007,014.40.The subscriptions do no ...

Core Viewpoint - Sol-Gel Technologies, Ltd. reported financial results for the first quarter of 2025, showing an increase in total revenue but a higher net loss compared to the same period in 2024 [2][4]. Financial Performance - Total revenue for the first quarter of 2025 was $1 million, a 100% increase from $0.5 million in the same period in 2024 [2]. - Research and development expenses rose to $8.8 million from $5.3 million in the first quarter of 2024, primarily due to supplier-led manufacturing development for SGT-610 [3]. - General and administrative expenses decreased to $1.3 million from $1.8 million in the same period in 2024, attributed to cost measures taken in 2024 [4]. - The net loss for the first quarter of 2025 was $8.8 million, compared to a net loss of $6.3 million in the first quarter of 2024, with a basic and diluted loss per share of $3.2 compared to $2.3 in 2024 [4]. Cash Position - As of March 31, 2025, Sol-Gel had $16.9 million in cash and cash equivalents, with no marketable securities, expected to fund operations into the first quarter of 2027 [5]. Company Overview - Sol-Gel Technologies focuses on developing and commercializing drug products for skin diseases, with FDA-approved products TWYNEO and EPSOLAY for acne and rosacea, respectively [6]. - The company's pipeline includes SGT-610, an Orphan Drug candidate for basal cell carcinoma prevention, and SGT-210 for rare skin keratodermas [7].

Core Points - Sol-Gel Technologies Ltd. announced a 10-for-1 reverse share split to increase the per share market price and regain compliance with Nasdaq's minimum bid price requirement [4][5][6] Group 1: Reverse Share Split Details - The reverse share split will consolidate every ten ordinary shares into one ordinary share, effective at 11:59 p.m. Eastern Time on May 2, 2025 [3][5] - The first trading day on Nasdaq under the new share structure is expected to be May 5, 2025, with the symbol "SLGL" remaining unchanged [3][4] - The par value of the ordinary shares will increase from NIS 0.1 to NIS 1.0, and the total share capital will adjust from 50 million to 5 million ordinary shares [6] Group 2: Shareholder Approval and Process - Shareholders approved the reverse split ratio at a special meeting on April 1, 2025, with the board of directors confirming the 10-for-1 ratio on April 9, 2025 [2] - Equiniti Trust Company, LLC will act as the exchange and transfer agent for the reverse split, and shareholders holding shares electronically will not need to take action to receive post-split shares [7] Group 3: Company Overview - Sol-Gel Technologies is focused on developing and commercializing drug products for skin diseases, with FDA-approved products including TWYNEO for acne and EPSOLAY for rosacea [8] - The company's pipeline includes SGT-610, an orphan drug candidate for Gorlin syndrome, and SGT-210, a topical drug candidate for rare skin keratodermas [9]

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced that, following the merger with Cyclo Therapeutics, Bill Conkling will be stepping down as CEO and assuming an advisory role wit ...

Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b tri ...